In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 30 for your search:
Drug:  bexarotene
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-20, NCI-V96-1050

2.

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-23, NCI-V97-1149

3.

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-24, NCI-V97-1151

4.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069T-25, NCI-V97-1292

5.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-49

6.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-48, BMC-C-7093-49, UCLA-0301086

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: MDA-DM-94098, NCI-V95-0621

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UCLA-HSPC-960630001, LIGAND-L1069-17, LIGAND-UCLA-HSPC-960630001, NCI-V97-1205

9.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: YALE-HIC-8644, LIGAND-YALE-HIC-8644, NCI-V96-0882

10.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-21, NCI-V96-0973

11.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-22, NCI-V97-1124

12.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-96061, LIGAND-MSKCC-96061, NCI-G97-1140

13.

Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-34, MSKCC-99008, UMN-9808M00110, NCT00003752

14.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MILL-61896, LIGAND-MILL-61896, NU-IRB-837-002, NCT00030589

15.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-01128, NCI-G01-2049, NCT00030849

16.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: D-0440, NCT00125359

17.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 050416, NCT00178841

18.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-098, MSKCC-05098, NCT00255801

19.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: J0675 CDR0000525989, P30CA006973, JHOC-J0675, JHOC-NA_00003076, J0675, NCT00425477

20.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0826, NCT00411632

21.

Phase: Phase II
Type: Treatment
Status: Unknown
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EISAI-2007-01-22, 2007-01-22, NCT00514293

22.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 04407, NCT00615784

23.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/06/009, CRUK-UCL-GEMBEX, EU-20841, EUDRACT 2006-000591-33, NCT00660231

24.

Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: MDA-DM-94045, NCI-V94-0497

25.

Phase: Phase I
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000271913, 5U19CA086809, BCM-H-9315, U19-CA-86809-2, NCT00055991
1   
New Search